Al-Madina Pharmaceuticals will hold web show today (Sunday) as part of the regulatory requirement to raise a capital worth Tk 50 million under book building method.
The company will raise the fund through a qualified investor offer (QIO) to be executed through SME platform of the Dhaka Stock Exchange (DSE).
At Sunday's web show, the company will uphold its current position along with putting light on the plans to be executed after raising capital from the qualified investors.
The company invites different qualified investors such as merchant bankers, mutual funds, banks, financial institutes, recognised provident funds, issuer of listed securities, and resident and non-resident Bangladeshis having a minimum net worth of Tk 0.02 million each, among others, to attend the web show.
Al-Madina Pharmaceuticals is a growing company in the pharmaceutical sector.
The company is engaged in manufacturing, buying, selling, refinement, import, export or otherwise of pharmaceutical, medical, and medical products and preparations, patent drugs and proprietary articles of all kinds, whether basic or derived and in all forms.
The company reported its earnings per share of Tk1.24, and net asset value per share of Tk12.54 for a period of six months ended on December 31, 2021.
The company has also reported its net profit of above Tk 18.47 million for July-December, 2021.
The company's paid-up capital has stood at Tk 154 million at the end of 2021.
According to red-herring prospectus, the company presently manufacturers 150 plus products of veterinary drugs such as antibacterial drugs, nutritional products, poultry vaccines, aqua products and daily injectable products ctc.
Prime Bank Investment Limited and EC Securities Limited are working as issue managers of the company.
